Effect of prophylactic application of doxycycline at the implant-abutment interface on the outcomes of implant therapy : a split-mouth randomized clinical trial
OBJECTIVES: Doxycycline hyclate is a controlled-release doxycycline polymer which can locally be applied. This study aimed to assess the effects of the prophylactic application of doxycycline hyclate at the implant-abutment interface on the short-term outcomes of implant therapy.
METHOD AND MATERIALS: The present split-mouth randomized clinical trial included 20 subjects who received two mandibular implants bilaterally (40 implants in total). In the test side (n = 20), doxycycline hyclate was injected at the implant-abutment interface at the time of delivery of final prosthesis. No intervention was performed for the control side (n = 20). The marginal bone level on mesial and distal implant surfaces, bleeding on probing, pocket probing depth, and incidence of peri-implant mucositis were recorded at baseline and after 3, 6, and 12 months.
RESULTS: Significant differences were found between the test and control sites, all favoring the test group, for marginal bone level changes at mesial and distal implant surfaces as well as for changes in pocket probing depth after 6 and 12 months. Furthermore, the numbers of implants with bleeding on probing and risk of developing peri-implant mucositis were significantly greater in the control group compared to the test group at 3-months, 6-months, and 12-months following baseline.
CONCLUSIONS: Within the limitations of this study, it can be concluded that prophylactic application of doxycycline hyclate at the implant-abutment interface results in reduced crestal bone resorption and pocket probing depth levels. In addition, it reduces the risk of developing peri-implant mucositis.
| Errataetall: |
CommentIn: Evid Based Dent. 2022 Dec;23(4):158-159. - PMID 36526844 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Quintessence international (Berlin, Germany : 1985) - 53(2022), 9 vom: 16. Sept., Seite 762-770 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arshad, Mahnaz [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.09.2022 Date Revised 12.01.2023 published: Print CommentIn: Evid Based Dent. 2022 Dec;23(4):158-159. - PMID 36526844 Citation Status MEDLINE |
|---|
| doi: |
10.3290/j.qi.b3320823 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346287642 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346287642 | ||
| 003 | DE-627 | ||
| 005 | 20231226031050.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3290/j.qi.b3320823 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346287642 | ||
| 035 | |a (NLM)36112019 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arshad, Mahnaz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of prophylactic application of doxycycline at the implant-abutment interface on the outcomes of implant therapy |b a split-mouth randomized clinical trial |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.09.2022 | ||
| 500 | |a Date Revised 12.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Evid Based Dent. 2022 Dec;23(4):158-159. - PMID 36526844 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVES: Doxycycline hyclate is a controlled-release doxycycline polymer which can locally be applied. This study aimed to assess the effects of the prophylactic application of doxycycline hyclate at the implant-abutment interface on the short-term outcomes of implant therapy | ||
| 520 | |a METHOD AND MATERIALS: The present split-mouth randomized clinical trial included 20 subjects who received two mandibular implants bilaterally (40 implants in total). In the test side (n = 20), doxycycline hyclate was injected at the implant-abutment interface at the time of delivery of final prosthesis. No intervention was performed for the control side (n = 20). The marginal bone level on mesial and distal implant surfaces, bleeding on probing, pocket probing depth, and incidence of peri-implant mucositis were recorded at baseline and after 3, 6, and 12 months | ||
| 520 | |a RESULTS: Significant differences were found between the test and control sites, all favoring the test group, for marginal bone level changes at mesial and distal implant surfaces as well as for changes in pocket probing depth after 6 and 12 months. Furthermore, the numbers of implants with bleeding on probing and risk of developing peri-implant mucositis were significantly greater in the control group compared to the test group at 3-months, 6-months, and 12-months following baseline | ||
| 520 | |a CONCLUSIONS: Within the limitations of this study, it can be concluded that prophylactic application of doxycycline hyclate at the implant-abutment interface results in reduced crestal bone resorption and pocket probing depth levels. In addition, it reduces the risk of developing peri-implant mucositis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a dental implants | |
| 650 | 4 | |a doxycycline | |
| 650 | 4 | |a peri-implant mucositis | |
| 650 | 4 | |a peri-implantitis | |
| 650 | 4 | |a randomized controlled trials | |
| 650 | 4 | |a treatment outcome | |
| 650 | 7 | |a Delayed-Action Preparations |2 NLM | |
| 650 | 7 | |a Dental Implants |2 NLM | |
| 650 | 7 | |a Doxycycline |2 NLM | |
| 650 | 7 | |a N12000U13O |2 NLM | |
| 700 | 1 | |a Mahgoli, Hoseinali |e verfasserin |4 aut | |
| 700 | 1 | |a Akhoundinasab, Foad |e verfasserin |4 aut | |
| 700 | 1 | |a Sadrai, Sima |e verfasserin |4 aut | |
| 700 | 1 | |a Shirani, Gholamreza |e verfasserin |4 aut | |
| 700 | 1 | |a Mahgoli, Mohammad Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Bassir, Seyed Hossein |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Quintessence international (Berlin, Germany : 1985) |d 1985 |g 53(2022), 9 vom: 16. Sept., Seite 762-770 |w (DE-627)NLM012684309 |x 1936-7163 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2022 |g number:9 |g day:16 |g month:09 |g pages:762-770 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3290/j.qi.b3320823 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2022 |e 9 |b 16 |c 09 |h 762-770 | ||